Welcome to our dedicated page for Axon Enterprise SEC filings (Ticker: AXON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Axon Enterprise, Inc. (NASDAQ: AXON), a public safety technology company that reports under the Exchange Act. Through these filings, investors can review how Axon describes its Connected Devices and Software & Services segments, its public safety operating system strategy and its capital structure.
Axon uses periodic and current reports, including Forms 10-K, 10-Q and 8-K, to disclose financial performance, segment results, annual recurring revenue metrics and material events. Recent Form 8-K filings referenced in company communications include shareholder letters detailing quarterly revenue growth, updates to revenue outlook, and additional information on the performance of Software & Services and Connected Devices. Other 8-K filings describe governance changes, such as the appointment of new directors, and capital markets activity, including privately negotiated exchanges of 0.50% convertible senior notes due 2027 for cash and common stock, and a notice of redemption for these notes with terms for redemption and conversion.
On Stock Titan, Axon’s SEC filings are updated in near real time as documents are posted to the EDGAR system. AI-powered summaries help explain lengthy filings by highlighting key topics such as segment performance, annual recurring revenue, future contracted bookings, note exchanges and redemptions, and other material disclosures. Users can also review insider and executive-related filings, such as Forms 3, 4 and 5, to track equity awards, stock transactions and governance developments.
Whether you are analyzing Axon’s financial condition, understanding its use of convertible notes, or reviewing disclosures about acquisitions and emergency communications strategy, this filings page offers a centralized view of AXON’s regulatory history with AI tools that surface the most important information from each document.
Axon Enterprise CHIEF REVENUE OFFICER Cameron Brooks reported a routine share withholding tied to equity compensation. On the transaction date, 5,849.7 shares of Common Stock were disposed of to cover tax obligations from the vesting of restricted stock units.
These shares were withheld rather than sold in the open market, reflecting a tax-withholding disposition under the company’s 2024 eXponential Stock Plan. After this event, Brooks directly held 51,695.69 shares of Axon common stock, as reported in the filing.
Axon Enterprise Inc — The Vanguard Group filed Amendment No. 12 to a Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Axon common stock. The filing explains that, in accordance with SEC Release No. 34-39538 (January 12, 1998), certain Vanguard subsidiaries and business divisions will report beneficial ownership separately following an internal realignment on January 12, 2026. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Axon Enterprise director Jeri Williams reported an open-market sale of common stock. On March 17, 2026, Williams sold 157 shares at a price of $490.00 per share. After the sale, Williams directly owned 1,159 shares of Axon common stock. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025, indicating it was scheduled in advance rather than timed discretionarily.
Axon Enterprise director Erika Nardini sold shares in an open-market trade. On March 17, 2026, she sold 198 shares of common stock at an average price of $506.579 per share. After this transaction, she directly holds 1,946 Axon common shares.
Axon Enterprise, Inc. reported that director Julie Anne Cullivan has informed the Board that she will not stand for re-election at the company’s 2026 Annual Meeting of Shareholders. She will continue to serve as a director until her current term expires at that meeting.
The company states that Ms. Cullivan’s decision is not due to any disagreement with Axon regarding its operations, policies, or practices. The Board expressed strong appreciation for her commitment, leadership, and contributions to Axon’s growth and progress during her years of service.
Axon Enterprise president Joshua Isner reported a series of open-market stock sales. On March 10, he sold a total of 34,581 shares of Axon common stock in 18 separate transactions, at prices generally in the low-to-mid $500s per share. After these sales, he continued to hold 214,921 shares directly, so he remains a significant shareholder. The filing notes that many trades were executed in multiple lots, with reported prices representing weighted averages within specified intraday price ranges.
Axon Enterprise CEO Patrick W. Smith reported selling 10,000 shares of common stock in multiple open-market transactions on March 9, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 12, 2025.
The trades were priced at reported weighted-average prices ranging from about $546.81 to $577.12 per share. After these transactions, Smith continues to hold 3,080,997 shares of Axon Enterprise common stock directly, indicating that the sale represents a small portion of his overall stake.
Axon Enterprise's Chief Revenue Officer, Cameron Brooks, reported an open-market sale of 1,221 shares of common stock. The shares were sold at an average price of $565.51 per share. After this transaction, Brooks directly holds about 57,545 shares, so the sale represents a small portion of his overall position. According to a footnote, the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025, indicating it was scheduled in advance rather than timed opportunistically.